Indication

Multiple myeloma

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells primarily within the bone marrow. Read more about Multiple myeloma

167 drugs 90 manufacturers

Advertisement

Drugs that treat it

Common Multiple myeloma therapies.

Showing 127–135 of 167 drugs

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS·MULTIPLE MYELOMA·+1
SINTETICA US LL

MELPHALAN HCL

NITROGEN MUSTARD DERIVATIVES·MULTIPLE MYELOMA
AVENACY, INC

CYCLOPHOSPHAMIDE

NITROGEN MUSTARD DERIVATIVES·RETINOBLASTOMA·+17
X-GEN PHARMACEU

CARMUSTINE

NITROSOUREAS·MALIGNANT BRAIN NEOPLASM·+6
SANDOZ

CARMUSTINE

NITROSOUREAS·MALIGNANT BRAIN NEOPLASM·+6
Avet Pharmaceuticals

MELPHALAN HCL

NITROGEN MUSTARD DERIVATIVES·MULTIPLE MYELOMA
DR. REDDY'S/NOV

CARMUSTINE

NITROSOUREAS·MALIGNANT BRAIN NEOPLASM·+6
AVET-NOVAPLUS
Filter & compare in the drug finder →Opens the drug finder with Multiple myeloma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Multiple myeloma.

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells primarily within the bone marrow.

It predominantly affects older adults and involves the hematopoietic and skeletal systems.

Pathophysiologically, the malignant expansion disrupts normal hematopoiesis and stimulates osteoclastic bone resorption while suppressing osteoblastic activity, accompanied by the overproduction of monoclonal immunoglobulins or free light chains.

Clinically, this leads to classic manifestations of end-organ damage, including osteolytic bone lesions, pathologic fractures, hypercalcemia, renal impairment, cytopenias such as anemia, and heightened susceptibility to infection.

Personalize your experience

Follow Multiple myeloma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it